Charles W. Drescher
Expertise in
11
conditions

Dr. Charles W. Drescher

Oncology
Swedish Medical Center
Swedish Cancer Institute Gynecologic Oncology And Pelvic Surgery - First Hill
1101 Madison Street, Suite 1500, 
Seattle, WA 
Accepting New Patients
Offers Telehealth
44 Years of Experience

Expertise in
11
conditions
Swedish Medical Center
Swedish Cancer Institute Gynecologic Oncology And Pelvic Surgery - First Hill
1101 Madison Street, Suite 1500, 
Seattle, WA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Dr. Drescher is a multiple time recipient of the Seattle Top Doctor Award and most recently received the 2024 Seattle Magazine Top Doc Award. Dr. Drescher’s goal is to provide the absolute best care for each and every patient. Potential treatment options are large and ever increasing. He works hard to ensure patients are aware and understand all options available to them and then work together to identify the optimal approach. Dr. Drescher listens carefully and works closely with a team of providers to ensure problems are addressed in a holistic way.

Dr. Drescher is rated as an Experienced provider by MediFind in the treatment of Amenorrhea. His top areas of expertise are Ovarian Cancer, Malignant Mixed Mullerian Tumor, Endometrial Cancer, Oophorectomy, and Salpingo-Oophorectomy.

His clinical research consists of co-authoring 53 peer reviewed articles and participating in 18 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 53 articles and participated in 18 clinical trials in the study of Amenorrhea.

Graduate Institution
University Of Michigan Medical School , 1982, 1982
Residency
University of Michigan Medical School , 1987
Specialties
Oncology
Licenses
Specialist in WA
Board Certifications
American Board Of Obstetrics And Gynecology
Fellowships
University of Michigan Medical School , 1989
Hospital Affiliations
Swedish Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Community Health
  • EPO
  • HMO
Coordinated Care
  • HMO
  • MANAGED MEDICAID PLAN
Group Health Cooperative
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Lifewise

Accepted plan types not found. Please verify directly with the provider.

Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
PacificSource
  • PPO
Premera
  • EPO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Prominence Health
  • EPO
  • PPO
Regence
  • EPO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 18 Less Insurance Carriers -

Locations

Swedish Cancer Institute Gynecologic Oncology and Pelvic Surgery - First Hill
1101 Madison Street, Suite 1500, Seattle, WA 98104
Call: 206-991-2000
Other Locations
Providence Regional Cancer Partnership
1717 13th Street, Everett, WA 98201
Call: 425-297-5500
Swedish First Hill
747 Broadway, Seattle, WA 98122
Call: 206-386-6000
Providence Gynecologic Oncology
1717 13th Street, Suite 300, Everett, WA 98201
Call: 425-297-5660
Swedish Edmonds
21601 76th Avenue West, Edmonds, WA 98026
Call: 425-640-4000

Additional Areas of Focus

Dr. Drescher has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Vaginal Cancer
Choriocarcinoma
Preeclampsia
Endometrial Cancer
Endometriosis
Gestational Trophoblastic Disease
Genital Herpes
Menopause
Uterine Prolapse
Vulvovaginitis
Breast Lump
Hysterectomy
Premature Ovarian Failure
Vaginismus
Cervical Dysplasia
Amenorrhea
Pelvic Floor Dysfunction
Vulvar Cancer
Polycystic Ovary Syndrome
Cervical Cancer
Endometritis
Asymptomatic Bacteriuria
Menorrhagia
Premenstrual Dysphoric Disorder
Pelvic Inflammatory Disease
Vulvodynia
Ectopic Pregnancy
View 17 Less Areas of Focus-

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


18 Clinical Trials

Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab in Combination With Talazoparib in Patients With SLFN11 Positive Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab in Combination With Talazoparib in Patients With SLFN11 Positive Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Procedure, Drug
Study Drugs: Atezolizumab, Talazoparib
Study Phase: Phase 2
Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients With Germline BRCA1 or BRCA2 Mutations
Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients With Germline BRCA1 or BRCA2 Mutations
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Procedure, Drug, Biological
Study Drugs: Olaparib, Pembrolizumab
Study Phase: Phase 2
Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma
Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Drug, Biological, Procedure
Study Drugs: Bendamustine Hydrochloride, Cyclophosphamide, Doxorubicin Hydrochloride, Lenalidomide, Obinutuzumab, Prednisone, Umbralisib, Vincristine Sulfate
Study Phase: Phase 2
A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC
A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Other, Drug, Procedure, Radiation
Study Drug: Atezolizumab
Study Phase: Phase 3
A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently With Radiotherapy Versus Radiotherapy Alone for Inflammatory Breast Cancer
A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently With Radiotherapy Versus Radiotherapy Alone for Inflammatory Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Drug, Procedure, Radiation, Other
Study Drug: Olaparib
Study Phase: Phase 2
NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study
NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Other, Procedure
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Procedure, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 2
A Randomized Phase II Study of Ruxolitinib (NSC-752295) in Combination With BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia (CML) Patients With Molecular Evidence of Disease
A Randomized Phase II Study of Ruxolitinib (NSC-752295) in Combination With BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia (CML) Patients With Molecular Evidence of Disease
Enrollment Status: Active_not_recruiting
Publish Date: December 18, 2025
Intervention Type: Drug, Other
Study Drugs: Bosutinib, Dasatinib, Nilotinib, Nilotinib Hydrochloride Monohydrate, Ruxolitinib, Ruxolitinib Phosphate
Study Phase: Phase 2
A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma
A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: December 05, 2025
Intervention Type: Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 2
A Phase II Study of AMG 510 in Participants With Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN LUNG-MAP SUB-STUDY)
A Phase II Study of AMG 510 in Participants With Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN LUNG-MAP SUB-STUDY)
Enrollment Status: Active_not_recruiting
Publish Date: December 05, 2025
Intervention Type: Drug
Study Drug: Sotorasib
Study Phase: Phase 2
A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: December 04, 2025
Intervention Type: Drug, Biological, Procedure, Other, Radiation
Study Drugs: Brentuximab, Dacarbazine, Doxorubicin, Filgrastim, Nivolumab, Pegfilgrastim, Vinblastine
Study Phase: Phase 3
Cluster Randomized Controlled Trial of Patient and Provider Decision Support to Increase Chemoprevention Informed Choice Among Women With Atypical Hyperplasia or Lobular Carcinoma In Situ - Making Informed Choices on Incorporating Chemoprevention Into Care (MiChoice)
Cluster Randomized Controlled Trial of Patient and Provider Decision Support to Increase Chemoprevention Informed Choice Among Women With Atypical Hyperplasia or Lobular Carcinoma In Situ - Making Informed Choices on Incorporating Chemoprevention Into Care (MiChoice)
Enrollment Status: Active_not_recruiting
Publish Date: September 17, 2025
Intervention Type: Other, Behavioral
Study Phase: Not Applicable
S1803, Phase III Study of Daratumumab/rHuPH20 (NSC-810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients With Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)
S1803, Phase III Study of Daratumumab/rHuPH20 (NSC-810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients With Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)
Enrollment Status: Active_not_recruiting
Publish Date: September 15, 2025
Intervention Type: Drug
Study Drugs: Lenalidomide, Daratumumab/rHuPH20
Study Phase: Phase 3
A Phase 1/2, Open-Label, Multiple Ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of AGEN2034 in Subjects With Metastatic or Locally Advanced Solid Tumors, With Expansion to Second Line Cervical Cancer
A Phase 1/2, Open-Label, Multiple Ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of AGEN2034 in Subjects With Metastatic or Locally Advanced Solid Tumors, With Expansion to Second Line Cervical Cancer
Enrollment Status: Completed
Publish Date: July 30, 2025
Intervention Type: Drug
Study Drug: AGEN-2034 PD-1 Antibody
Study Phase: Phase 1/Phase 2
A Phase II Trial of Sacituzumab Govitecan (IMMU-132) (NSC #820016) for Patients With HER2-Negative Breast Cancer and Brain Metastases
A Phase II Trial of Sacituzumab Govitecan (IMMU-132) (NSC #820016) for Patients With HER2-Negative Breast Cancer and Brain Metastases
Enrollment Status: Active_not_recruiting
Publish Date: April 24, 2025
Intervention Type: Biological
Study Drug: Sacituzumab Govitecan
Study Phase: Phase 2
A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery of a Proactive Financial Navigation Intervention (CREDIT)
A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery of a Proactive Financial Navigation Intervention (CREDIT)
Enrollment Status: Active_not_recruiting
Publish Date: April 03, 2025
Intervention Type: Other, Behavioral
Study Phase: Not Applicable
A Phase 2, Multicenter, Single Arm, Open Label Study to Evaluate the Efficacy and Safety of AK104 in Subjects With Recurrent or Metastatic Cervical Cancer
A Phase 2, Multicenter, Single Arm, Open Label Study to Evaluate the Efficacy and Safety of AK104 in Subjects With Recurrent or Metastatic Cervical Cancer
Enrollment Status: Completed
Publish Date: February 28, 2025
Intervention Type: Biological
Study Drug: AK104
Study Phase: Phase 2
The nCYT Study: A Powered Study to Evaluate the Sensitivity and Specificity of Cytological Evaluation of Fallopian Tube Samples Collected by the Cytuity in Determining the Presence of Malignancy
The nCYT Study: A Powered Study to Evaluate the Sensitivity and Specificity of Cytological Evaluation of Fallopian Tube Samples Collected by the Cytuity in Determining the Presence of Malignancy
Enrollment Status: Completed
Publish Date: January 20, 2021
Intervention Type: Device
View 17 Less Clinical Trials

53 Total Publications

Multimodal Spatial Profiling Reveals Immune Suppression and Microenvironment Remodeling in Fallopian Tube Precursors to High-Grade Serous Ovarian Carcinoma.
Multimodal Spatial Profiling Reveals Immune Suppression and Microenvironment Remodeling in Fallopian Tube Precursors to High-Grade Serous Ovarian Carcinoma.
Journal: bioRxiv : the preprint server for biology
Published: October 10, 2024
View All 53 Publications
Similar Doctors
Dan S. Veljovich
Advanced in Amenorrhea
Dr. Dan S. Veljovich
Oncology
Advanced in Amenorrhea
Dr. Dan S. Veljovich
Oncology

Swedish Cancer Institute Gynecologic Oncology And Pelvic Surgery - First Hill

1101 Madison Street, Suite 1500, 
Seattle, WA 
 (0.1 miles away)
206-991-2000
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Dr. Dan Veljovich is a multiple time recipient of the Seattle Top Doctor Award and most recently received the 2024 Seattle Magazine Top Doc Award. With an attention to respecting autonomy, calming fears and partnering with patients to help them make treatment decisions in line with their own goals, Dr. Veljovich embodies compassionate care. He feels blessed to be able to help women maintain their dignity and preserve their quality of life while undergoing surgical or medical treatments. Dr. Veljovich is rated as an Advanced provider by MediFind in the treatment of Amenorrhea. His top areas of expertise are Ovarian Cancer, Malignant Mixed Mullerian Tumor, Testicular Yolk Sac Tumor, Oophorectomy, and Hernia Surgery.

Amy E. Bondurant
Advanced in Amenorrhea
Dr. Amy E. Bondurant
Oncology
Advanced in Amenorrhea
Dr. Amy E. Bondurant
Oncology

Providence Regional Cancer Partnership

1717 13th Street, 0, 
Everett, WA 
 (27.6 miles away)
425-297-5500
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Dr. BonDurant is a multiple-time recipient of the Seattle Top Doctor Award and most recently received the 2024 Seattle Magazine Top Doc Award. Dr. BonDurant believes what makes a great physician is not only skill, but the ability to genuinely care about patients. To be this type of physician every day, she strives to provide innovative quality medicine with sincere appreciation, compassion and respect for her patients. It's her privilege to care for such strong and courageous women during difficult times in their lives. Dr. Bondurant is rated as an Advanced provider by MediFind in the treatment of Amenorrhea. Her top areas of expertise are Malignant Mixed Mullerian Tumor, Ovarian Cancer, Endometrial Cancer, Oophorectomy, and Hernia Surgery.

Fernanda B. Musa
Advanced in Amenorrhea
Dr. Fernanda B. Musa
Oncology
Advanced in Amenorrhea
Dr. Fernanda B. Musa
Oncology

Providence Regional Cancer Partnership

1717 13th Street, 0, 
Everett, WA 
 (27.6 miles away)
425-297-5500
Languages Spoken:
English, Portuguese
See accepted insurances
Accepting New Patients
Offers Telehealth

Dr. Musa is a multiple-time recipient of the Seattle Top Doctor Award and most recently received the 2023 Seattle Met Top Doc Award. Dr. Musa prides herself in taking care of her patients as a whole. She is happy to offer them minimally invasive surgery whenever possible and feels privileged to also be able to care for them throughout their treatment. Dr. Musa is rated as an Advanced provider by MediFind in the treatment of Amenorrhea. Her top areas of expertise are Malignant Mixed Mullerian Tumor, Sertoli-Leydig Cell Tumor, Ovarian Cancer, Hysterectomy, and Oophorectomy.

VIEW MORE AMENORRHEA DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Drescher's expertise for a condition
ConditionClose
  • Elite
  • Ovarian Cancer
    Dr. Drescher is
    Elite
    . Learn about Ovarian Cancer.
    See more Ovarian Cancer experts
    • Advanced
    • Cervical Cancer
      Dr. Drescher is
      Advanced
      . Learn about Cervical Cancer.
      See more Cervical Cancer experts
    • Endometrial Cancer
      Dr. Drescher is
      Advanced
      . Learn about Endometrial Cancer.
      See more Endometrial Cancer experts
    • Endometrial Stromal Sarcoma
      Dr. Drescher is
      Advanced
      . Learn about Endometrial Stromal Sarcoma.
      See more Endometrial Stromal Sarcoma experts
    • Lump in the Abdomen
      Dr. Drescher is
      Advanced
      . Learn about Lump in the Abdomen.
      See more Lump in the Abdomen experts
    • Malignant Mixed Mullerian Tumor
      Dr. Drescher is
      Advanced
      . Learn about Malignant Mixed Mullerian Tumor.
      See more Malignant Mixed Mullerian Tumor experts
    • Ovarian Carcinosarcoma
      Dr. Drescher is
      Advanced
      . Learn about Ovarian Carcinosarcoma.
      See more Ovarian Carcinosarcoma experts
    View All 10 Advanced Conditions
    • Experienced
    • BRCA Positive Breast Cancer
      Dr. Drescher is
      Experienced
      . Learn about BRCA Positive Breast Cancer.
      See more BRCA Positive Breast Cancer experts
    • Breast Cancer
      Dr. Drescher is
      Experienced
      . Learn about Breast Cancer.
      See more Breast Cancer experts
    • Desmoplastic Small Round Cell Tumor
      Dr. Drescher is
      Experienced
      . Learn about Desmoplastic Small Round Cell Tumor.
      See more Desmoplastic Small Round Cell Tumor experts
    • Hernia Surgery
      Dr. Drescher is
      Experienced
      . Learn about Hernia Surgery.
      See more Hernia Surgery experts
    • Lung Adenocarcinoma
      Dr. Drescher is
      Experienced
      . Learn about Lung Adenocarcinoma.
      See more Lung Adenocarcinoma experts
    • Melanoma
      Dr. Drescher is
      Experienced
      . Learn about Melanoma.
      See more Melanoma experts
    View All 13 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile
    For Patients
    • Our Story
    • How MediFind Works
    • Conditions A-Z
    • Doctor Directory
    • Symptoms Directory
    • Procedures Directory
    • Treatment Directory
    • Drug Directory
    • Infusion Center Finder
    • FAQ
    • Contact Us
    For Providers and Practices
    • Claim Your Profile
    • Newsroom
    Business Solutions
    • Provider
    • Network Solutions
    Additional Resources
    • Consumer Health Data Privacy Policy
    • Privacy Policy
    • Terms of Use
    • Advertising Policy
    • Content Policy
    Subscribe to our newsletter

    Sign up to stay informed about MediFind and get wellness sent your way.

    Close

      By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

      Bullet PinMediFind
      Follow us on
      This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
      © 2026 All Rights Reserved

      Request an Appointment

      If you are experiencing a medical emergency, call 9-1-1.

      MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

      Patient Details

      This information is for the patient who will be seen at the appointment.

        Close

        Returning patient? Use your address on file with the provider.

        Insurance Details

        Please provide information of the primary insurance holder as the practice may require this information to schedule.

        Insurance Provider *
        Insurance ProviderClose

        Appointments Details

        Let’s get more information about your appointment.

                  0 / 1000
                  0 / 1000
                  By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.